ALTAVILLA, Giuseppe
 Distribuzione geografica
Continente #
EU - Europa 2.143
NA - Nord America 42
AS - Asia 29
AF - Africa 2
Totale 2.216
Nazione #
IT - Italia 2.077
US - Stati Uniti d'America 38
IE - Irlanda 34
VN - Vietnam 18
PL - Polonia 16
CA - Canada 4
NL - Olanda 4
CZ - Repubblica Ceca 3
ES - Italia 3
GB - Regno Unito 3
BD - Bangladesh 2
DE - Germania 2
IN - India 2
CN - Cina 1
EG - Egitto 1
GH - Ghana 1
ID - Indonesia 1
IR - Iran 1
MK - Macedonia 1
NP - Nepal 1
OM - Oman 1
PH - Filippine 1
TR - Turchia 1
Totale 2.216
Città #
Messina 530
Dublin 34
Dong Ket 18
Warsaw 16
Catania 9
Redmond 9
Acireale 6
Fleming Island 5
Ottawa 4
Rome 4
Council Bluffs 3
Ashburn 2
Barcelona 2
Boardman 2
Dhaka 2
London 2
Accra 1
Aci Castello 1
Angeles City 1
Ankara 1
Bengaluru 1
Bologna 1
Brooklyn 1
Cambridge 1
Cardiff 1
Chennai 1
Dalian 1
Las Vegas 1
Madrid 1
Medan 1
Milan 1
Mountain View 1
Muscat 1
Pescantina 1
Shreveport 1
Skopje 1
Trieste 1
Verona 1
Wilmington 1
Totale 671
Nome #
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study, file de3e52af-a03c-762d-e053-3705fe0a30e0 1.924
Targeted drugs in small-cell lung cancer, file de3e52b0-636e-762d-e053-3705fe0a30e0 39
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy, file de3e52b0-f3cf-762d-e053-3705fe0a30e0 23
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy, file de3e52b3-9ad6-762d-e053-3705fe0a30e0 23
Liquid biopsy for lung cancer early detection, file de3e52b3-9ad0-762d-e053-3705fe0a30e0 20
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients, file de3e52b3-d530-762d-e053-3705fe0a30e0 16
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20), file de3e52b3-5ea7-762d-e053-3705fe0a30e0 14
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer, file de3e52b3-96a1-762d-e053-3705fe0a30e0 12
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: results from the Italian cohort of an expanded access program, file de3e52b2-0df9-762d-e053-3705fe0a30e0 11
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role, file de3e52b0-633b-762d-e053-3705fe0a30e0 9
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients, file de3e52b2-0e2a-762d-e053-3705fe0a30e0 9
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy, file de3e52b2-8dd8-762d-e053-3705fe0a30e0 9
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued?, file de3e52af-6c1f-762d-e053-3705fe0a30e0 8
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia., file de3e52ae-ef40-762d-e053-3705fe0a30e0 7
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20), file de3e52b3-a737-762d-e053-3705fe0a30e0 7
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors., file de3e52ae-a447-762d-e053-3705fe0a30e0 5
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?, file de3e52b0-0ab3-762d-e053-3705fe0a30e0 5
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer, file de3e52b0-6254-762d-e053-3705fe0a30e0 5
Mucocutaneous toxicity induced by pegylated liposomal doxorubicin. A single institution, retrospective case series, file de3e52b0-a049-762d-e053-3705fe0a30e0 5
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review., file de3e52ae-c024-762d-e053-3705fe0a30e0 4
Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer, file de3e52b0-54c6-762d-e053-3705fe0a30e0 4
Efficacy of clindamycin phosphate and benzoyl peroxide gel (DUAC(®) ) in the treatment of EGFR inhibitors-associated acneiform eruption., file de3e52b0-59bc-762d-e053-3705fe0a30e0 4
Recent developments in the use of immunotherapy in non-small cell lung cancer, file de3e52b0-674a-762d-e053-3705fe0a30e0 4
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast., file de3e52ae-ab9e-762d-e053-3705fe0a30e0 3
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance, file de3e52ae-c0db-762d-e053-3705fe0a30e0 3
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings, file de3e52ae-e5fd-762d-e053-3705fe0a30e0 3
Nail toxicities induced by liposomal doxorubicin: A retrospective case series, file de3e52b1-139a-762d-e053-3705fe0a30e0 3
Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study, file de3e52b2-0e2c-762d-e053-3705fe0a30e0 3
Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study, file de3e52b3-81df-762d-e053-3705fe0a30e0 3
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data, file 0ecfa333-e9dd-4a32-a26d-918cbdea93c2 2
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases, file de3e52ae-c9c8-762d-e053-3705fe0a30e0 2
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive, file de3e52af-ab7f-762d-e053-3705fe0a30e0 2
Feasibility of cell-free circulating tumor DNA testing for lung cancer, file de3e52b0-6417-762d-e053-3705fe0a30e0 2
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer, file de3e52b0-f23e-762d-e053-3705fe0a30e0 2
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape, file de3e52b0-f278-762d-e053-3705fe0a30e0 2
null, file de3e52b1-46e1-762d-e053-3705fe0a30e0 2
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC), file de3e52b3-d428-762d-e053-3705fe0a30e0 2
Mucocutaneous toxicity induced by pegylated liposomal doxorubicin. A single institution, retrospective case series, file de3e52b4-324d-762d-e053-3705fe0a30e0 2
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC), file 2eed7d50-29a3-461d-9b64-77eec34b0339 1
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS, file de3e52ae-a3d8-762d-e053-3705fe0a30e0 1
Pharmacogenomics in non-small-cell lung cancer chemotherapy., file de3e52ae-a448-762d-e053-3705fe0a30e0 1
Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design, file de3e52ae-a6cb-762d-e053-3705fe0a30e0 1
null, file de3e52ae-c701-762d-e053-3705fe0a30e0 1
Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma., file de3e52ae-f8d5-762d-e053-3705fe0a30e0 1
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions., file de3e52af-9e33-762d-e053-3705fe0a30e0 1
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., file de3e52af-a23a-762d-e053-3705fe0a30e0 1
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors, file de3e52b0-62c0-762d-e053-3705fe0a30e0 1
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population, file de3e52b1-9f99-762d-e053-3705fe0a30e0 1
null, file de3e52b3-4b9f-762d-e053-3705fe0a30e0 1
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study, file de3e52b3-8328-762d-e053-3705fe0a30e0 1
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications, file de3e52b3-c7f1-762d-e053-3705fe0a30e0 1
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma, file de3e52b3-d534-762d-e053-3705fe0a30e0 1
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation, file de3e52b4-8a4c-762d-e053-3705fe0a30e0 1
Totale 2.218
Categoria #
all - tutte 2.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.618


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 1 0 0 0 0 0 1 0 0
2019/202023 0 1 1 0 1 0 0 0 4 0 8 8
2020/2021102 3 1 6 6 24 2 2 1 15 24 0 18
2021/202225 0 0 0 9 3 5 2 1 1 1 3 0
2022/2023102 0 1 1 3 10 8 5 4 48 10 8 4
2023/20248 1 2 5 0 0 0 0 0 0 0 0 0
Totale 2.218